Derivados de carboxamidina e seu uso no tratamento de doenças vasculares

"DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Car...

Full description

Saved in:
Bibliographic Details
Main Authors LASZLO DENES, ZITA JEGESNE CSAKAI, MAGDOLNA BATHONE TOROK, LASZLO UROGDI, EDE MARVANYOS
Format Patent
LanguagePortuguese
Published 28.12.2004
Edition7
Online AccessGet full text

Cover

Loading…
More Information
Summary:"DERIVADOS DE CARBOXAMIDINA E SEU USO NO TRATAMENTO DE DOENçAS VASCULARES". A presente invenção refere-se a derivados de carboxamidina para composições farmacêuticas que os contenham e ao uso dos mesmos na preparação de composições farmacêuticas para o tratamento de doenças vasculares. Carboxamidine derivatives (I)-(III) are used for treating or preventing vascular diseases. Carboxamidine derivatives of formula (I)-(III) or their salts are used for treating or preventing vascular diseases. R 1>, R 2>1-6C alkyl (optionally substituted by phenyl), or H, or NR 1>R 2>T; T : 5-7 membered saturated heterocyclyl optionally containing further N or O heteroatoms (optionally substituted by 1 or 2 OH, oxo or benzyl); A : phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or CN), or 5- or 6-membered heteroaryl containing at least one N, O or S and optionally having an N-oxide structure on the N heteroatom; n : 0-2; z : 0 or 1; X : halo or NR 4>R 5>; R 3>-R 5>H or 1-6C alkyl; Y : H, OH, halo or 1-22C acyloxy, and X 1>O, provided that: (1) when R 4>and R 5>are simultaneously H, then Y is not OH; (2) when Y is not halo, then NR 1>R 2>is T, A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom and z is 1; (3) when X is halo and Y is hydroxy or acyloxy, then NR 1>R 1>is T; (4) when R 1>and R 2>are 1-6C alkyl (optionally substituted by phenyl), H, and NR 1>R 2>is 5-7 membered saturated heterocyclyl containing N or O, then A is heteroaryl containing O, S or N-containing heteroaryl having a N-oxide structure on the N heteroatom; and (5) when A is phenyl (optionally substituted by 1 or 2 1-4C alkyl, 1-4C haloalkyl, NO 2or halo), or 5- or 6-membered N-containing heteroaryl, then NR 1>R 2>is T. N.B: The formulae (I)-(III) are not shown in the specification. Independent claims are included for the following: (1) new compounds (I), with the further proviso that when Y is H and/or X is NR 4>R 5>, then NR 1>R 2>is T or A is N-containing heteroaryl optionally having an N-oxide structure on the N heteroatom; (2) new compounds (II), with the further proviso that when Y is not halo, then NR 1>R 2>is T and A is N-containing heteroaryl optionally having a N-oxide structure on the N heteroatom, and (3) new compounds (III). ACTIVITY : Vasotropic; Cardiovascular-Gen. In a wounding migration assay in an endothelial cell culture using wounded monolayers of human umbilical vein endothelial cells (HUVEC), results showed that N-[2-chloro-3-(1-piperidinyl)propoxy]-3-nitro-benzimidoyl-chloride hydrochloride gave number of cells/mm 2>at 24 hours of 60, compared to 30 for 5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine used as a control. MECHANISM OF ACTION : None given.
Bibliography:Application Number: BR20030306778